Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 777-783, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922146
ABSTRACT
Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have been approved for first-line and second-line treatment in patients with metastatic NSCLC. However, only 15% to 30% of patients with advanced NSCLC can achieve sustained remission and long-term survival from immunotherapy. Therefore, biomarker for predicting the efficacy of immunotherapy is particularly important. This article reviews the relevant literatures on predictive biomarkers for immunotherapy of NSCLC and provides direction for future research.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Biomarkers
/
Biomarkers, Tumor
/
Carcinoma, Non-Small-Cell Lung
/
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
/
Immunologic Factors
/
Immunotherapy
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS